ImmunityBio Financial Ratios
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.51+0.60 (+6.05%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ImmunityBio ratio analysis
ImmunityBio earned a net margin of -310.2% in FY 2025, up from -2804.8% a year earlier. Gross margin was 99.3% compared with a median of 100.0% over the prior 3 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
ImmunityBio financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 16.40 | 132.89 | 4,105.07 | 8,447.89 | 2,533.77 | 8,307.95 | 672.09 | 2,239.27 | 8,040.48 | 10,657.27 |
| Price / book | — | — | — | — | — | — | 12.26 | 0.72 | 1.65 | 1.60 |
| Gross margin | 99.3% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating margin | -226.0% | -2,334.2% | -58,239.5% | -146,374.2% | -35,361.9% | -36,509.1% | -7,095.9% | -209,338.3% | -220,266.7% | -282,954.5% |
| Net margin | -310.2% | -2,804.8% | -93,761.4% | -173,569.6% | -37,129.6% | -36,669.6% | -7,165.2% | -204,736.2% | -214,273.3% | -274,565.9% |
| Free cash flow margin | -272.6% | -2,700.1% | -63,881.2% | -173,196.3% | -32,974.5% | -28,660.0% | -7,102.5% | -162,729.8% | -185,766.7% | -102,620.5% |
| Return on equity (ROE) | — | — | — | — | — | — | -130.7% | -65.9% | -44.1% | -41.2% |
| Return on assets (ROA) | -70.0% | -108.0% | -115.6% | -115.0% | -74.0% | -100.2% | -110.2% | -52.9% | -38.5% | -38.1% |
| Current ratio | 5.10 | 3.36 | 5.05 | 0.28 | 0.91 | 1.64 | 4.82 | 3.26 | 6.35 | 16.34 |
| Revenue growth | 668.3% | 2,270.6% | 159.2% | -74.3% | 54.4% | -72.5% | 4,585.1% | 4.4% | 2.3% | -81.4% |